| Browse All

Contineum Therapeutics, Inc. (CTNM)

Healthcare | Biotechnology | San Diego, United States | NasdaqGS
13.53 USD +0.23 (1.729%) ⇧ (April 17, 2026, 4 p.m. EDT)
After hours: 13.53

Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 11, 2026, 3:59 p.m. EDT

CTNM is a speculative stock with high volatility and weak fundamentals. The recent price movement shows some short-term momentum, but the overall trend is mixed with a lack of clear direction. The stock has no dividend history and is not recommended for long-term investment. Short-term traders may consider buying calls if the price breaks above the 14.0 level, but the overall outlook remains uncertain.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.071716
AutoTheta0.072794
AutoETS0.072850
AutoARIMA0.072851

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 80%
H-stat 0.57
Ljung-Box p 0.000
Jarque-Bera p 0.302
Excess Kurtosis -1.13
Attribute Value
Sector Healthcare
Debt to Equity Ratio 3.161
Market Cap 505,156,544
Forward P/E -6.22
Beta 1.39
Website https://www.contineum-tx.com

As of April 11, 2026, 3:59 p.m. EDT: Options speculators are showing mixed signals. For the near-term (April 17), there is a concentration of open interest and volume around the 12.5 strike, indicating potential support or resistance. However, the presence of higher strike puts (like 17.5) with higher IV suggests some bearish sentiment. For the longer-dated expirations, the activity is minimal, with most open interest concentrated on the ATM and slightly out-of-the-money strikes. This suggests a lack of clear directional bias from options traders, with more focus on volatility management.


Info Dump

Attribute Value
52 Week Change 1.6868687
Address1 3,565 General Atomics Court
Address2 Suite 200
All Time High 22.0
All Time Low 3.35
Ask 13.63
Ask Size 1
Average Daily Volume10 Day 296,160
Average Daily Volume3 Month 291,827
Average Volume 291,827
Average Volume10Days 296,160
Beta 1.385
Bid 13.43
Bid Size 1
Book Value 6.993
City San Diego
Compensation As Of Epoch Date 1,735,603,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 13.53
Current Ratio 27.496
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 13.695
Day Low 13.255
Debt To Equity 3.161
Display Name Contineum Therapeutics
Earnings Timestamp 1,772,744,400
Earnings Timestamp End 1,778,702,400
Earnings Timestamp Start 1,778,702,400
Ebitda -67,736,000
Ebitda Margins 0.0
Enterprise To Ebitda -3.698
Enterprise Value 250,510,560
Eps Current Year -2.05571
Eps Forward -2.175
Eps Trailing Twelve Months -2.17
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 13.9623
Fifty Day Average Change -0.43230057
Fifty Day Average Change Percent -0.030961987
Fifty Two Week Change Percent 168.68686
Fifty Two Week High 16.33
Fifty Two Week High Change -2.8000002
Fifty Two Week High Change Percent -0.17146358
Fifty Two Week Low 3.35
Fifty Two Week Low Change 10.18
Fifty Two Week Low Change Percent 3.0388062
Fifty Two Week Range 3.35 - 16.33
Financial Currency USD
First Trade Date Milliseconds 1,712,323,800,000
Float Shares 25,360,502
Forward Eps -2.175
Forward P E -6.22069
Free Cashflow -36,918,876
Full Exchange Name NasdaqGS
Full Time Employees 51
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.01001
Held Percent Institutions 0.90744
Implied Shares Outstanding 37,336,036
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,024-04-05
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Long Name Contineum Therapeutics, Inc.
Market us_market
Market Cap 505,156,544
Market State CLOSED
Max Age 86,400
Message Board Id finmb_558548528
Most Recent Quarter 1,767,139,200
Net Income To Common -59,978,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 505,156,567
Number Of Analyst Opinions 6
Open 13.51
Operating Cashflow -55,312,000
Operating Margins 0.0
Payout Ratio 0.0
Phone 858 333 5280
Post Market Change 0.0
Post Market Change Percent 0.0
Post Market Price 13.53
Post Market Time 1,776,456,604
Previous Close 13.3
Price Eps Current Year -6.5816674
Price Hint 2
Price To Book 1.9347919
Profit Margins 0.0
Quick Ratio 26.98
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 0.23
Regular Market Change Percent 1.72932
Regular Market Day High 13.695
Regular Market Day Low 13.255
Regular Market Day Range 13.255 - 13.695
Regular Market Open 13.51
Regular Market Previous Close 13.3
Regular Market Price 13.53
Regular Market Time 1,776,456,000
Regular Market Volume 423,196
Return On Assets -0.17379999
Return On Equity -0.26131
Sand P52 Week Change 0.36506534
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 32,673,536
Shares Percent Shares Out 0.0744
Shares Short 2,779,583
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 2,548,283
Short Name Contineum Therapeutics, Inc.
Short Percent Of Float 0.0911
Short Ratio 7.36
Source Interval 15
State CA
Symbol CTNM
Target High Price 29.0
Target Low Price 14.0
Target Mean Price 22.0
Target Median Price 21.5
Total Cash 262,896,000
Total Cash Per Share 7.041
Total Debt 8,250,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -2.17
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 11.0409
Two Hundred Day Average Change 2.4890995
Two Hundred Day Average Change Percent 0.22544353
Type Disp Equity
Volume 423,196
Website https://www.contineum-tx.com
Zip 92,121